These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9324278)

  • 1. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; O'Brien S; Beran M; Koller C; Pierce S; Kornblau S; Estey E; Keating MJ; Talpaz M
    Leukemia; 1997 Oct; 11(10):1610-6. PubMed ID: 9324278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
    Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
    Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
    J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
    Giles FJ; Kantarjian H; O'Brien S; Rios MB; Cortes J; Beran M; Koller C; Keating M; Talpaz M
    Leuk Lymphoma; 2001 Apr; 41(3-4):309-19. PubMed ID: 11378543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
    Nese M; de Bellis R; Urtiarte R; Di Landro J
    Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
    Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
    Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
    Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
    Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
    Cortes J; Kantarjian H; O'Brien S; Robertson LE; Pierce S; Talpaz M
    Am J Med; 1996 Apr; 100(4):452-5. PubMed ID: 8610733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
    Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
    Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Smith TL; O'Brien S; Pierce S; Kornblau S; Beran M; Keating MJ; Talpaz M
    J Clin Oncol; 1998 Mar; 16(3):882-9. PubMed ID: 9508169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha].
    Hong H; Qiu JY; Lai YY; Shi Y; He Q; Dang H; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):269-73. PubMed ID: 12844411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results.
    Guilhot F; Abgrall JF; Harousseau JL; Bauters F; Brice P; Dine G; Tilly H; Ifrah N; Cassasus P; Rochant H
    Leuk Lymphoma; 1993; 11 Suppl 1():181-3. PubMed ID: 8251893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
    Maloisel F; Guerci A; Guyotat D; Ifrah N; Michallet M; Reiffers J; Tertain G; Blanc M; Bauduer F; Brière J; Abgrall JF; Pegourie-Bandelier B; Solary E; Cambier N; Coso D; Vilque JP; Delain M; Harousseau JL; Rousselot P; Belhadj K; Morice P; Attal J; Chabin M; Chastang C; Guilhot J; Guilhot F;
    Leukemia; 2002 Apr; 16(4):573-80. PubMed ID: 11960335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
    Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
    Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
    Beck JR; Guilhot J; Giles FJ; Aoki N; Wirt DP; Guilhot F
    Leuk Lymphoma; 2001 Mar; 41(1-2):117-24. PubMed ID: 11342363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
    Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
    Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
    Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
    Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.